Regenxbio

Regenxbio is a biotechnology company that develops and commercializes gene therapies. The company's core technology involves using viral vectors to deliver therapeutic genes to treat various diseases.

Why it’s in the news: It is in the news due to ongoing regulatory scrutiny, including FDA pauses and reversals related to its gene therapy trials, and its plans to seek approval for a treatment for Duchenne muscular dystrophy.

Latest on Regenxbio

• STAT+: FDA pauses Regenxbio gene therapy trial again due to safety concerns
• STAT+: Pharmalittle: We’re reading about Medicaid obesity-drug coverage, a Regenxbio gene therapy, and more
• STAT+: Wagering on FDA changes, Regenxbio will submit Duchenne gene therapy for approval
• STAT+: FDA reverses course on Regenxbio’s childhood gene therapy after rejection

Connections

5 entities linked to Regenxbio across the news graph.